Literature DB >> 16098116

A double-blind, crossover study of Biotène Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia.

S A Shahdad1, C Taylor, S C Barclay, I N Steen, P M Preshaw.   

Abstract

This study assessed the efficacy of the Bioxtra (BX) and Biotène Oralbalance (OB) systems in the treatment of post-radiotherapy xerostomia. In a double-blind, crossover study, 20 patients with post-radiotherapy xerostomia were randomly allocated to receive either OB then BX, or vice versa, each product for 2 weeks, with a 1 week wash-out period in between. Subject-based dry mouth scores derived from 100-mm visual analogue scales were recorded at days 0 and 14 of each 2-week period, together with subjective perception of changes in dry mouth symptoms. Both treatments were effective, resulting in reduction of visual analogue scale scores from day 0-14. Between-groups comparisons identified that BX achieved significantly better improvements compared with OB for the perception of dry mouth and improvements in speech and was also rated as more pleasant to use than OB (P < 0.05). In conclusion, both treatments were effective in alleviating the symptoms of post-radiotherapy xerostomia, although BX achieved superiority in some of the outcomes assessed compared with OB.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098116     DOI: 10.1111/j.1365-2354.2005.00587.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  24 in total

Review 1.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

2.  Evaluation of xerostomia in hematopoietic cell transplantation by a simple capacitance method device.

Authors:  Yuko Sugiura; Yoshihiko Soga; Sachiko Nishide; Kotoe Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

3.  With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed.

Authors:  Yuko Sugiura; Yoshihiko Soga; Ichiro Tanimoto; Susumu Kokeguchi; Sachiko Morishige-Nishide; Kotoe Itami-Kono; Kanayo Takahashi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Kokoro Yamabe; Soichiro Tsutani; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2014-09-20       Impact factor: 3.603

4.  Cytotoxic effects of a chlorhexidine mouthwash and of an enzymatic mouthwash on human gingival fibroblasts.

Authors:  Ana Sofia Coelho; Mafalda Laranjo; Ana Cristina Gonçalves; Anabela Paula; Siri Paulo; Ana Margarida Abrantes; Francisco Caramelo; Manuel Marques Ferreira; Mário Jorge Silva; Eunice Carrilho; Maria Filomena Botelho
Journal:  Odontology       Date:  2019-10-17       Impact factor: 2.634

5.  Assessment of xerostomia and its impact on quality of life in head and neck cancer patients undergoing radiation therapy.

Authors:  Pinelopi-Theopisti Memtsa; Maria Tolia; Ioannis Tzitzikas; John Bizakis; Kyriaki Pistevou-Gombaki; Martha Charalambidou; Chrysoula Iliopoulou; George Kyrgias
Journal:  Mol Clin Oncol       Date:  2017-03-17

6.  Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation.

Authors:  Yuko Sugiura; Yoshihiko Soga; Kokoro Yamabe; Soichiro Tsutani; Ichiro Tanimoto; Hiroshi Maeda; Susumu Kokeguchi; Nobuharu Fujii; Fumihiko Ishimaru; Mitsune Tanimoto; Fusanori Nishimura; Shogo Takashiba
Journal:  Support Care Cancer       Date:  2009-12-05       Impact factor: 3.603

Review 7.  Saliva substitutes for the treatment of radiation-induced xerostomia--a review.

Authors:  Sebastian Hahnel; Michael Behr; Gerhard Handel; Ralf Bürgers
Journal:  Support Care Cancer       Date:  2009-06-04       Impact factor: 3.603

8.  The Effect of a Combination Saliva Substitute for the Management of Xerostomia and Hyposalivation.

Authors:  R C Lapiedra; G E Gómez; B P Sánchez; A A Pereda; M D Turner
Journal:  J Maxillofac Oral Surg       Date:  2015-03-14

9.  The efficacy of Xialine in patients with Sjögren's syndrome: a single-blind, cross-over study.

Authors:  Esin Alpöz; Pelin Güneri; Gonca Onder; Hülya Cankaya; Yasemin Kabasakal; Timur Köse
Journal:  Clin Oral Investig       Date:  2007-11-14       Impact factor: 3.573

10.  Wetting the whistle: neurotropic factor improves salivary function.

Authors:  Adam Swick; Randall J Kimple
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.